Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia.
Frontometaphyseal dysplasia (FMD) is a progressive, sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2016
|
| _version_ | 1797077868030722048 |
|---|---|
| author | Wade, E Daniel, P Jenkins, Z McInerney-Leo, A Morgan, T Addor, M Ades, L Bertola, D Bohring, A Carter, E Cho, T Duba, H Fletcher, E Kim, C Krakow, D Morava, E Neuhann, T Superti-Furga, A Veenstra-Knol, I Wieczorek, D Wilson, L Hennekam, R Sutherland-Smith, A Strom, T Wilkie, A Brown, M Duncan, E Markie, D Robertson, S |
| author_facet | Wade, E Daniel, P Jenkins, Z McInerney-Leo, A Morgan, T Addor, M Ades, L Bertola, D Bohring, A Carter, E Cho, T Duba, H Fletcher, E Kim, C Krakow, D Morava, E Neuhann, T Superti-Furga, A Veenstra-Knol, I Wieczorek, D Wilson, L Hennekam, R Sutherland-Smith, A Strom, T Wilkie, A Brown, M Duncan, E Markie, D Robertson, S |
| author_sort | Wade, E |
| collection | OXFORD |
| description | Frontometaphyseal dysplasia (FMD) is a progressive, sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations except for an increased tendency to form keloid scars. Using whole exome sequencing and targeted Sanger sequencing in 19 FMD individuals with no identifiable FLNA mutation, we identified mutations in two genes - MAP3K7, encoding transforming growth factor β (TGFβ)-activated kinase (TAK1) and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n=15) de novo mutation (c.1454C>T, p.Pro485Leu) proximal to the coiled-coil domain of TAK1, and three missense mutations affecting the kinase domain (c.208G>C, p.Glu70Gln; c.299T>A, p.Val100Glu and c.502G>C, p.Gly168Arg). Notably these latter three subjects had a milder FMD phenotype. A further de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerise or bind TAB2, but it does increase TAK1 autophosphorylation and alters the activity of more than one signalling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations may be mediated by misregulation of signalling co-ordinated through the TAK1 signalling complex. |
| first_indexed | 2024-03-07T00:24:12Z |
| format | Journal article |
| id | oxford-uuid:7d8f5f21-e383-4387-9985-3a761cf57b13 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:24:12Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7d8f5f21-e383-4387-9985-3a761cf57b132022-03-26T21:04:33ZMutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7d8f5f21-e383-4387-9985-3a761cf57b13Symplectic Elements at OxfordElsevier2016Wade, EDaniel, PJenkins, ZMcInerney-Leo, AMorgan, TAddor, MAdes, LBertola, DBohring, ACarter, ECho, TDuba, HFletcher, EKim, CKrakow, DMorava, ENeuhann, TSuperti-Furga, AVeenstra-Knol, IWieczorek, DWilson, LHennekam, RSutherland-Smith, AStrom, TWilkie, ABrown, MDuncan, EMarkie, DRobertson, SFrontometaphyseal dysplasia (FMD) is a progressive, sclerosing skeletal dysplasia affecting the long bones and skull. The cause of FMD in some individuals is gain-of-function mutations in FLNA, although how these mutations result in a hyperostotic phenotype remains unknown. Approximately one half of individuals with FMD have no identified mutation in FLNA and are phenotypically very similar to individuals with FLNA mutations except for an increased tendency to form keloid scars. Using whole exome sequencing and targeted Sanger sequencing in 19 FMD individuals with no identifiable FLNA mutation, we identified mutations in two genes - MAP3K7, encoding transforming growth factor β (TGFβ)-activated kinase (TAK1) and TAB2, encoding TAK1-associated binding protein 2 (TAB2). Four mutations were found in MAP3K7, including one highly recurrent (n=15) de novo mutation (c.1454C>T, p.Pro485Leu) proximal to the coiled-coil domain of TAK1, and three missense mutations affecting the kinase domain (c.208G>C, p.Glu70Gln; c.299T>A, p.Val100Glu and c.502G>C, p.Gly168Arg). Notably these latter three subjects had a milder FMD phenotype. A further de novo mutation was found in TAB2 (c.1705G>A, p.Glu569Lys). The recurrent mutation does not destabilize TAK1, or impair its ability to homodimerise or bind TAB2, but it does increase TAK1 autophosphorylation and alters the activity of more than one signalling pathway regulated by the TAK1 kinase complex. These findings show that dysregulation of the TAK1 complex produces a close phenocopy of FMD caused by FLNA mutations. Furthermore they suggest that the pathogenesis of some of the filaminopathies caused by FLNA mutations may be mediated by misregulation of signalling co-ordinated through the TAK1 signalling complex. |
| spellingShingle | Wade, E Daniel, P Jenkins, Z McInerney-Leo, A Morgan, T Addor, M Ades, L Bertola, D Bohring, A Carter, E Cho, T Duba, H Fletcher, E Kim, C Krakow, D Morava, E Neuhann, T Superti-Furga, A Veenstra-Knol, I Wieczorek, D Wilson, L Hennekam, R Sutherland-Smith, A Strom, T Wilkie, A Brown, M Duncan, E Markie, D Robertson, S Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title | Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title_full | Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title_fullStr | Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title_full_unstemmed | Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title_short | Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. |
| title_sort | mutations in map3k7 that alter the activity of the tak1 signaling complex cause frontometaphyseal dysplasia |
| work_keys_str_mv | AT wadee mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT danielp mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT jenkinsz mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT mcinerneyleoa mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT morgant mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT addorm mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT adesl mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT bertolad mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT bohringa mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT cartere mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT chot mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT dubah mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT fletchere mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT kimc mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT krakowd mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT moravae mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT neuhannt mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT supertifurgaa mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT veenstraknoli mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT wieczorekd mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT wilsonl mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT hennekamr mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT sutherlandsmitha mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT stromt mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT wilkiea mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT brownm mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT duncane mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT markied mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia AT robertsons mutationsinmap3k7thataltertheactivityofthetak1signalingcomplexcausefrontometaphysealdysplasia |